Pursuant to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we inform you that w.e.f. 18-October-2025, Dr. Umesh Luthra has resigned as Independent ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries Ltd has informed the stock exchanges of changes to its board effective 18 October 2025. Dr. Umesh Luthra has resigned as an Independent Director, citing personal pre-occupation, and confirmed there are no other material reasons for his exit. To fill the vacancy, Dr. Vijay Ojha has been appointed as an additional Independent Director on the same date. Dr. Ojha brings over 30 years of pharmaceutical industry experience spanning API, formulation development, scale-up and commercialization, with prior stints at Lupin, Sun Pharma, IPCA Laboratories and Flavine Inc. (USA), and holds a PhD in Chemistry. The changes appear to be a routine board reshuffle with no governance red flags mentioned.
Shareholders should view this as a routine board-level change with a like-for-like replacement of an Independent Director. No impact on operations, financials or share price is expected, though the incoming director's strong pharma R&D background could be seen as a positive addition to the board's expertise.